Anthem Biosciences Ipo Day 1: Check Subscription Status, Gmp, Allotment Date & More

The first nationalist offering (IPO) of Anthem Biosciences was disconnected to time decent bidding from nan investors arsenic it crossed nan halfway people during nan first time of nan bidding process arsenic nan bidding was mostly led by HNI and unit bidders. The issue, which kicked disconnected connected Thursday, July 10, shall adjacent for bidding connected Monday, July 14.

Anthem Biosciences is trading its shares successful nan value set of Rs 540-570 apiece. Investors tin use for a minimum of 26 shares and its multiples thereafter. It is looking to raise Rs 3,395 crore via IPO, which is wholly a caller stock waste of up to 5,95,61,404 equity shares by promoters and different shareholders of nan company.

According to nan data, nan investors made bids for 2,49,17,516 equity shares, aliases 57 per cent, compared to nan 4,40,70,682 equity shares offered for nan subscription by 3.30 p.m. connected Monday, July 14, 2025. The three-day bidding for nan rumor shall proceed for three-days.

The allocation for unit investors was subscribed 47 per cent, while nan information reserved for non-institutional investors (NIIs) saw a subscription of 1.04 times. Allocation of labor was booked 66 per cent. However, nan quota group speech for qualified organization bidders (QIBs) was subscribed 36 per cent arsenic of nan aforesaid time.

Incorporated successful 2006, Bengaluru-based Anthem Biosciences is an innovation-driven and technology-focused statement research, development, and manufacturing statement (CRDMO) pinch afloat integrated operations encompassing supplier discovery, development, and manufacturing processes.

The grey marketplace premium (GMP) of Anthem Biosciences has surged higher contempt nan rising volatility successful nan broader markets. Last heard, nan institution was commanding a premium of Rs 105-110 per stock successful nan unofficial market, suggesting 17-18 per cent listing gains for nan investors.

Analysts mostly person a affirmative position connected this rumor and propose subscribing to it citing its beardown financial performance, marketplace leadership, reasonable valuations, and beardown business model. However, complete OFS quality and strictness successful nan overseas marketplace are nan awesome concerns for nan issue.

Anthem Biosciences has built a beardown world presence, backed by a important level of expertise from its founders and guidance team. It holds a unsocial position successful nan manufacture led by its integrated capabilities to manufacture some mini molecules and biologics, coupled pinch a divers scope of modalities, said Nirmal Bang Securities.

"Anthem IPO is issued astatine a somewhat little valuation 71x to FY25 EPS erstwhile compared pinch its peers. However, we judge company’s beardown business model, attraction connected driving nan maturation adopting sustainability and humanities robust financial capacity to pull higher valuation successful nan future. Thus, we urge 'subscribe' to nan issue," it said.

Anthem Biosciences raised Rs 1,016.02 crore from 60 anchor investors. For nan financial twelvemonth ended connected March 31, 2025, Anthem Biosciences reported a nett profit of Rs 451.26 crore pinch a gross of Rs 1,930.29 crore. It clocked a nett profit of Rs 367.31 crore pinch a gross of Rs 1,483.07 crore for nan fiscal twelvemonth 2023-24. It shall bid a full marketplace capitalization of 31,867.39 crore.

The institution has reserved shares worthy Rs 8.25 crore for its eligible employees, who will get a discount of Rs 50 successful nan IPO. Of nan nett offer, 50 per cent shares shall beryllium reserved for qualified organization bidders, while non-institutional investors (NIIs) will person 15 per cent for nan allocation. Retail investors will person 35 per cent of allocation successful nan IPO.

We delegate 'subscribe' standing to this IPO arsenic nan institution is nan fastest increasing Indian CRDMO on pinch differentiated business exemplary catering to nan needs of mini pharmaceutical and emerging biotech companies, from find to commercialized manufacturing, said Marwadi Financial Services. "It is disposable astatine a reasonable valuation arsenic compared to its peers," it said.

JM Financial, Citigroup Global Markets India, JP Morgan India and Nomura Financial Advisory & Securities (India) are nan book-running lead managers of nan Anthem Biosciences IPO, while Kfin Technologies is nan registrar for nan issue. Shares of nan institution shall beryllium listed connected some BSE and NSE pinch Monday, July 21.